Could a diabetes drug shield ICU survivors from heart and kidney failure?
NCT ID NCT07025629
First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 25 times
Summary
This study tests whether the drug dapagliflozin can reduce deaths and serious heart or kidney problems in people leaving the intensive care unit (ICU). About 600 adults who needed a breathing machine or blood pressure support will take either the drug or a placebo for up to 12 months. The goal is to see if this daily pill can lower the high risk of complications after a critical illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Saint Louis
RECRUITINGParis, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Saint Louis Hospital
NOT_YET_RECRUITINGParis, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.